Natural Product (NP) Details
General Information of the NP (ID: NP6128) | |||||
---|---|---|---|---|---|
Name |
Gossypol
|
||||
Synonyms |
(-)-Gossypol; 90141-22-3; (+)-Gossypol; Pogosin; Tash 1; racemic-Gossypol; (R)-(-)-Gossypol; (R)-Gossypol; (+-)-Gossypol; (+/-)-Gossypol; CCRIS 2689; NSC56817; NSC 56817; NSC 624336; BRN 1917878; CHEMBL51483; AI3-22957; 20300-26-9; 1,1',6,6',7,7'-Hexahydroxy-5,5'-diisopropyl-3,3'-dimethyl-[2,2'-binaphthalene]-8,8'-dicarbaldehyde; 2,2'-bi[8-Formyl-1,6,7-trihydroxy-5-isopropyl-3-methylnaphthalene]; 2,2'-Bis(1,6,7-trihydroxy-3-methyl-5-isopropyl-8-aldehydonaphthalene); NSC624336; Gossypol acetate
Click to Show/Hide
|
||||
Species Origin | Gossypium herbaceum ... | Click to Show/Hide | |||
Gossypium herbaceum | |||||
Disease | Prostate cancer [ICD-11: 2C82] | Phase 2 | [1] | ||
Structure |
![]() |
Click to Download Mol2D MOL |
|||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
Formula |
C30H30O8
|
||||
PubChem CID | |||||
Canonical SMILES |
CC1=CC2=C(C(=C(C(=C2C(C)C)O)O)C=O)C(=C1C3=C(C4=C(C=C3C)C(=C(C(=C4C=O)O)O)C(C)C)O)O
|
||||
InChI |
1S/C30H30O8/c1-11(2)19-15-7-13(5)21(27(35)23(15)17(9-31)25(33)29(19)37)22-14(6)8-16-20(12(3)4)30(38)26(34)18(10-32)24(16)28(22)36/h7-12,33-38H,1-6H3
|
||||
InChIKey |
QBKSWRVVCFFDOT-UHFFFAOYSA-N
|
||||
CAS Number |
CAS 20300-26-9
|
||||
Herb ID | |||||
SymMap ID | |||||
TTD Drug ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
TRAIL/Apo2L | Lung cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) |
Combination Info
![]() |
|||||
Molecule(s)
Regulation |
Up-regulation | Activity | CASP3 | Molecule Info |
Pathway MAP
|
|
In-vitro Model | NCI-H460 | CVCL_0459 | Lung large cell carcinoma | Homo sapiens | ||
NCI-H322 | CVCL_1556 | Lung adenocarcinoma | Homo sapiens | |||
Experimental
Result(s) |
Gossypol profoundly sensitizes thoracic cancer cells to the cytotoxic effect of Apo2L/TRAIL via activation of the mitochondria-dependent death signaling pathway. | |||||
Imatinib | Mantle cell lymphoma | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [3] | |||||
Detail(s) |
Combination Info
![]() |
|||||
Molecule(s)
Regulation |
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | BCL-xL | Molecule Info |
Pathway MAP
|
||
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | MCL1 | Molecule Info |
Pathway MAP
|
||
Biological
Regulation |
Up-regulation | Cytochrome c release | ||||
In-vitro Model | K-562 | CVCL_0004 | Chronic myelogenous leukemia | Homo sapiens | ||
Experimental
Result(s) |
Gossypol and its combination with imatinib induce apoptosis in human chronic myeloid leukemic cells. | |||||
Zoledronic | Mineral excesses | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [4] | |||||
Detail(s) |
Combination Info
![]() |
|||||
Molecule(s)
Regulation |
Up-regulation | Expression | BAD | Molecule Info |
Pathway MAP
|
|
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | BIRC2 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | BIRC3 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | BIRC5 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | CDKN1B | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | CLSPN | Molecule Info | |||
Up-regulation | Expression | FAS | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | HMOX1 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | HSP20 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | HSPD1 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | ML-IAP | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | PON2 | Molecule Info | |||
Down-regulation | Expression | TP53 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | DU145 | CVCL_0105 | Prostate carcinoma | Homo sapiens | ||
Experimental
Result(s) |
GP significantly enhances the anti-tumor activity of ZA in hormone- and drug-resistant prostate cancer cells by targeting many pivotal apoptosis-related proteins. | |||||
BRD4770 | Pancreatic cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [5] | |||||
Detail(s) |
Combination Info
![]() |
|||||
Molecule(s)
Regulation |
Up-regulation | Expression | MAP1LC3A | Molecule Info |
Pathway MAP
|
|
Biological
Regulation |
Increase | Autophagosome formation | ||||
In-vitro Model | MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | ||
HPAC | CVCL_3517 | Pancreatic adenocarcinoma | Homo sapiens | |||
PANC-1 | CVCL_0480 | Pancreatic ductal adenocarcinoma | Homo sapiens | |||
HeLa | CVCL_0030 | Endocervical adenocarcinoma | Homo sapiens | |||
PC-3 | CVCL_0035 | Prostate carcinoma | Homo sapiens | |||
Experimental
Result(s) |
The combination of gossypol and BRD4770 increased LC3-II levels and the autophagosome number in PANC-1 cells, and the compound combination appears to act in a BNIP3-dependent manner, suggesting that these compounds act together to induce autophagy-related cell death in pancreatic cancer cells. | |||||
5-fluorouracil | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Augmenting Drug Sensitivity | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [6] | |||||
Detail(s) |
Combination Info
![]() |
|||||
Molecule(s)
Regulation |
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
|
Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | TYMS | Molecule Info |
Pathway MAP
|
||
In-vitro Model | HT-29 | CVCL_0320 | Colon adenocarcinoma | Homo sapiens | ||
HCT 116 | CVCL_0291 | Colon carcinoma | Homo sapiens | |||
RKO | CVCL_0504 | Colon carcinoma | Homo sapiens | |||
Experimental
Result(s) |
Gossypol sensitizes the antitumor activity of 5-FU through down-regulation of thymidylate synthase in human colon carcinoma cells. | |||||
Doxorubicin | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [7] | |||||
Detail(s) |
Combination Info
![]() |
|||||
Molecule(s)
Regulation |
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Cleavage | CASP9 | Molecule Info |
Pathway MAP
|
||
Biological
Regulation |
Increase | Cell cycle arrest in S phase | ||||
In-vitro Model | SW982 | CVCL_1734 | Biphasic synovial sarcoma | Homo sapiens | ||
Experimental
Result(s) |
Combination therapy with L gossypol and low-concentration doxorubicin inhibited cell proliferation and induced apoptosis in SW982 HSSCs at a significantly greater level compared with either treatment alone. | |||||
β. A List of Drug(s) Whose Resistance can be Reversed by This NP | ||||||
Gemcitabine | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Reversing Drug Resistance | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [8] | |||||
Detail(s) |
Combination Info
![]() |
|||||
Molecule(s)
Regulation |
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | BCL-xL | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | PMAIP1 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | CNE-1 | CVCL_6888 | Human nasopharyngeal carcinoma | Homo sapiens | ||
CNE-2 | CVCL_6889 | Human nasopharyngeal carcinoma | Homo sapiens | |||
HK-1 | CVCL_7047 | Lung large cell carcinoma | Homo sapiens | |||
AGS | CVCL_0139 | Gastric adenocarcinoma | Homo sapiens | |||
SNU-1 | CVCL_0099 | Gastric adenocarcinoma | Homo sapiens | |||
YCC-16 | CVCL_9649 | Gastric adenocarcinoma | Homo sapiens | |||
SK-BR-3 | CVCL_0033 | Breast adenocarcinoma | Homo sapiens | |||
T-47D | CVCL_0553 | Invasive breast carcinoma | Homo sapiens | |||
MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | |||
HONE | Nasopharyngeal carcinoma | Homo sapiens | ||||
Experimental
Result(s) |
Combination therapy with gossypol reveals synergism against gemcitabine resistance in cancer cells with high BCL-2 expression. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Apoptosis regulator Bcl-2 (BCL-2) | Molecule Info | [9] | |
KEGG Pathway | NF-kappa B signaling pathway | Click to Show/Hide | ||
2 | HIF-1 signaling pathway | |||
3 | Sphingolipid signaling pathway | |||
4 | Protein processing in endoplasmic reticulum | |||
5 | PI3K-Akt signaling pathway | |||
6 | Apoptosis | |||
7 | Adrenergic signaling in cardiomyocytes | |||
8 | Focal adhesion | |||
9 | Neurotrophin signaling pathway | |||
10 | Cholinergic synapse | |||
11 | Amyotrophic lateral sclerosis (ALS) | |||
12 | Toxoplasmosis | |||
13 | Tuberculosis | |||
14 | Hepatitis B | |||
15 | Epstein-Barr virus infection | |||
16 | Pathways in cancer | |||
17 | MicroRNAs in cancer | |||
18 | Colorectal cancer | |||
19 | Prostate cancer | |||
20 | Small cell lung cancer | |||
NetPath Pathway | IL5 Signaling Pathway | Click to Show/Hide | ||
2 | TCR Signaling Pathway | |||
3 | IL2 Signaling Pathway | |||
4 | IL3 Signaling Pathway | |||
5 | Leptin Signaling Pathway | |||
6 | RANKL Signaling Pathway | |||
7 | TSLP Signaling Pathway | |||
Panther Pathway | Apoptosis signaling pathway | Click to Show/Hide | ||
2 | Oxidative stress response | |||
3 | CCKR signaling map ST | |||
Pathway Interaction Database | Role of Calcineurin-dependent NFAT signaling in lymphocytes | Click to Show/Hide | ||
2 | IL2-mediated signaling events | |||
3 | IL2 signaling events mediated by PI3K | |||
4 | Ceramide signaling pathway | |||
5 | Direct p53 effectors | |||
6 | RXR and RAR heterodimerization with other nuclear receptor | |||
7 | ATF-2 transcription factor network | |||
8 | C-MYB transcription factor network | |||
9 | HIV-1 Nef: Negative effector of Fas and TNF-alpha | |||
10 | Caspase Cascade in Apoptosis | |||
11 | Signaling events mediated by Stem cell factor receptor (c-Kit) | |||
12 | EPO signaling pathway | |||
13 | IL2 signaling events mediated by STAT5 | |||
14 | Validated targets of C-MYC transcriptional repression | |||
Reactome | Activation of BAD and translocation to mitochondria | Click to Show/Hide | ||
2 | BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members | |||
3 | The NLRP1 inflammasome | |||
WikiPathways | DNA Damage Response (only ATM dependent) | Click to Show/Hide | ||
2 | Senescence and Autophagy in Cancer | |||
3 | IL-2 Signaling Pathway | |||
4 | FAS pathway and Stress induction of HSP regulation | |||
5 | Focal Adhesion | |||
6 | Kit receptor signaling pathway | |||
7 | IL-3 Signaling Pathway | |||
8 | Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | |||
9 | Apoptosis | |||
10 | Nanoparticle triggered autophagic cell death | |||
11 | Amyotrophic lateral sclerosis (ALS) | |||
12 | Integrated Pancreatic Cancer Pathway | |||
13 | Corticotropin-releasing hormone | |||
14 | Interleukin-11 Signaling Pathway | |||
15 | Prostate Cancer | |||
16 | miR-targeted genes in muscle cell - TarBase | |||
17 | miR-targeted genes in lymphocytes - TarBase | |||
18 | miR-targeted genes in leukocytes - TarBase | |||
19 | Integrated Breast Cancer Pathway | |||
20 | Integrated Cancer pathway | |||
21 | Intrinsic Pathway for Apoptosis | |||
22 | Apoptosis Modulation and Signaling | |||
23 | TP53 Network | |||
24 | Influenza A virus infection | |||
25 | IL-5 Signaling Pathway |























